Valérie Boilet

P26 - Development and Validation of care pathway quality indicators for Stroke and Chronic Coronary Syndrome using French administrative healthcare database: The DELIQUA-CNV Project

Fadoua El Hafa, S. Domecq, Valérie Boilet, J. P. Legrand et autres

fr (code pays fourni par la source)

Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers

Vincent Bouteloup, Nicolas Villain, Jean‐Sébastien Vidal, Fernando González‐Ortiz et autres

Importance: Blood phosphorylated tau 217 (p-tau217) showed good performance in predicting brain amyloidosis. However, the importance of detailed cognitive phenotyping in patients without dementia when interpreting p-tau217 results remains unclear. Objective: To assess whether accuracy, negative predictive value (NPV), and positive predictive …

fr, se (code pays fourni par la source)

Développement et validation d'indicateurs de qualité des parcours de soins pour les patients atteints d'accident vasculaire cérébral et de syndrome coronarien chronique à partir des données du SNDS : projet DELIQUA-CNV

Fadoua El Hafa, S. Domecq, Valérie Boilet, J.-P. Legrand et autres

INTRODUCTION: Dans le cadre de la réforme du système de santé, le projet DELIQUA-CNV vise à développer et valider des indicateurs de qualité de parcours des syndromes coronariens chroniques (SCC) et des accidents vasculaires cérébraux (AVC) à partir du SNDS:1) réhospitalisations pour …

fr (code pays fourni par la source)

Predicting sojourn times across dementia disease stages, institutionalization, and mortality

Ashley Tate, Vincent Bouteloup, Ingrid S. van Maurik, Delphine Jean et autres

INTRODUCTION: Inferring the timeline from mild cognitive impairment (MCI) to severe dementia is pivotal for patients, clinicians, and researchers. Literature is sparse and often contains few patients. We aim to determine the time spent in MCI, mild-, moderate-, severe dementia, and institutionalization …

se, fr, nl, si (code pays fourni par la source)

Diabetes Mellitus and Cognition

Éric Frison, Cécile Proust‐Lima, Jean‐François Mangin, Marie‐Odile Habert et autres

ObjectiveTo assess the role of biomarkers of Alzheimer disease (AD), neurodegeneration, and small vessel disease (SVD) as mediators in the association between diabetes mellitus and cognition. MethodsThe study sample was derived from MEMENTO, a cohort of French adults recruited in memory clinics …

fr, us, ca (code pays fourni par la source)

A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial

Yves Lévy, Christine Lacabaratz, Édouard Lhomme, Aurélie Wiedemann et autres

In this placebo-controlled phase II randomized clinical trial, we evaluated the safety and immunogenicity of a therapeutic prime-boost vaccine strategy using a recombinant DNA vaccine (GTU-MultiHIV B clade) followed by a boost vaccination with a lipopeptide vaccine (HIV-LIPO-5) in HIV-infected patients on …

fr, ch (code pays fourni par la source)

PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Sodiomon B. Sirima, Laura Richert, Arnaud Chêne, Amadou T. Konaté et autres

Burkina Faso, fr, de (code pays fourni par la source)

OC 8582 A PHASE IA/B STUDY TO ASSESS SAFETY AND IMMUNOGENICITY OF PLACENTAL MALARIA VACCINE CANDIDATE: PRELIMINARY RESULTS OF THE PRIMALVAC TRIAL

Amadou T. Konaté, Laura Richert, Arnaud Chêne, Jean‐Philippe Semblat et autres

Background Adhesion of P. falciparum-infected erythrocytes (PEs) to placental chondroitin-4-sulfate (CSA) has been linked to severe placental malaria (PM) outcomes. Evidence strongly supports the VAR2CSA variant surface antigen mediating PEs CSA-binding phenotype as the leading candidate for a PM vaccine. This study …

Burkina Faso, fr, de (code pays fourni par la source)

Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial

Romain Palich, Jade Ghosn, Antoine Chaillon, Valérie Boilet et autres

OBJECTIVES: This study aimed to determine the timing and level of HIV rebound in blood and seminal plasma and to characterize the HIV rebounding populations after antiretroviral treatment interruption (ATI) in HIV-1-infected participants enrolled in a therapeutic vaccine trial. DESIGN: A 12-week …

fr, us (code pays fourni par la source)

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

Jean‐Luc Meynard, Laëtitia Moinot, Roland Landman, Amel Besseghir et autres

Background: Sparing of antiretroviral drug classes could reduce the toxicity and cost of maintenance treatment for HIV infection. Objectives: To evaluate the non-inferiority of efficacy and the safety of lopinavir/ritonavir (r) monotherapy versus a single-tablet regimen of efavirenz, emtricitabine and tenofovir (EFV/FTC/TDF) …

fr (code pays fourni par la source)

Étude du rebond virologique dans le sperme après l’arrêt du traitement antirétroviral, au cours d’un essai vaccinal thérapeutique mené en double aveugle (VRI02/ANRS149-LIGHT)

Romain Palich, Jade Ghosn, Antoine Chaillon, Valérie Boilet et autres

fr, us (code pays fourni par la source)

Continuous versus intermittent treatment strategies during primary HIV-1 infection

Cécile Goujard, Dominique Émilie, Caroline Roussillon, Véronique Godot et autres

OBJECTIVES: The ANRS-112 INTERPRIM trial assessed whether fixed-cycles of antiretroviral treatment interruption (ART-STI) combined or not with pegylated interferon alpha-2b (peg-IFN) could lower viral load and achieve a healthier immune system in patients diagnosed during primary HIV-1-infection (PHI). DESIGN AND METHODS: Patients …

fr, gb (code pays fourni par la source)